RxDoctor Payments Data

Jin Sung, APRN

Family · Dallas, TXNPI 1740943596

Payments from drug & device makers

$3,149in general payments, 2019–2025

Across 120 payments — averaging $26.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$944
  • Merck$816
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$332
  • Boehringer Ingelheim$310
  • Cvrx, Inc.$266
  • Novartis$155
  • plus $325 from 6 others

What the payments were for

  • Food & beverage$3,135100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,149 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$4,402
Medicare patients
20
Services billed
53

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan257$208,207
FarxigaDapagliflozin Propanediol110$85,730
JardianceEmpagliflozin111$78,122
BrilintaTicagrelor49$34,907
VerquvoVericiguat29$21,086
EliquisApixaban30$19,094
VascepaIcosapent Ethyl20$7,355
Metoprolol Succinate174$1,287
Atorvastatin Calcium125$1,034
Torsemide32$906
Spironolactone177$708
Isosorbide Dinitrate15$665
Carvedilol120$484
ClopidogrelClopidogrel Bisulfate19$476
Digoxin52$433

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$155$208,207257 claims
AstraZenecaFarxiga, Brilinta$944$120,637159 claims
Boehringer IngelheimJardiance$310$78,122111 claims
MerckVerquvo$816$21,08629 claims
PfizerEliquis$38$19,09430 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 15,456 family providers in Texas.

Other family in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →